Study	Experimental Events Total Ev	Control vents Total	Risk Ratio	RR 95%-CI Weight
Measures = Nasopha NCT01241591 NCT01276639 NCT01309737 NCT01815424 NCT01882439 NCT01877668 Common effect mode Heterogeneity: I ² = 0%,	30 330 31 360 30 381 9 90 7 132 6 104 1397	21 329 20 363 32 382 8 88 10 131 4 107 1400		1.42 [0.83; 2.44] 7.3% 1.56 [0.91; 2.69] 6.9% 0.94 [0.58; 1.52] 11.0% 1.10 [0.44; 2.72] 2.8% 0.69 [0.27; 1.77] 3.5% 1.54 [0.45; 5.31] 1.4% 1.19 [0.92; 1.55] 32.8%
Measures = Upper re NCT01241591 NCT01276639 NCT01309737 NCT01815424 NCT01882439 NCT01877668 Common effect mode Heterogeneity: I ² = 0%,	4 330 24 360 21 381 9 90 6 132 5 104 1397	6 329 17 363 18 382 10 88 10 131 2 107 1400		0.66 [0.19; 2.33] 2.1% 1.42 [0.78; 2.60] 5.9% 1.17 [0.63; 2.16] 6.2% 0.88 [0.38; 2.06] 3.5% 0.60 [0.22; 1.59] 3.5% 2.57 [0.51; 12.96] 0.7% 1.10 [0.79; 1.53] 21.8%
Measures = CPK elex NCT01241591 NCT01276639 NCT01309737 NCT01877668 Common effect model Heterogeneity: $I^2 = 5\%$,	16 330 26 360 15 381 0 104 el 1175 $\hat{\tau} = 0.0249, p = 0.37$	15 329 13 363 7 382 1 107 —— 1181		1.06 [0.53; 2.12] 5.2% 2.02 [1.05; 3.86] 4.5% 2.15 [0.89; 5.21] 2.4% 0.34 [0.01; 8.32] 0.5% 1.58 [1.05; 2.37] 12.6%
Measures = Hyperch NCT01241591 NCT01276639 NCT01309737 NCT01815424 Common effect mode Heterogeneity: $I^2 = 0\%$,	14 330 9 360 20 381 8 90 1161	11 329 9 363 20 382 5 88 1162	——————————————————————————————————————	1.27 [0.58; 2.75] 3.8% 1.01 [0.40; 2.51] 3.1% 1.00 [0.55; 1.83] 6.9% 1.56 [0.53; 4.60] 1.7% 1.13 [0.77; 1.67] 15.6%
Measures = Headach NCT01276639 NCT01309737 NCT01882439 NCT01877668 Common effect mode Heterogeneity: I ² = 8%,	24 360 18 381 10 132 10 104 977	25 363 16 382 5 131 4 107 983		0.97 [0.56; 1.66] 8.6% 1.13 [0.58; 2.18] 5.5% 1.98 [0.70; 5.65] 1.7% 2.57 [0.83; 7.94] 1.4% 1.25 [0.87; 1.79] 17.2%
Common effect mode Heterogeneity: $I^2 = 0\%$, Test for subgroup differe	$\hat{t} = 0, p = 0.80$	6126 4 (<i>p</i> = 0.71)	0.1 0.51 2 10	1.22 [1.05; 1.42] 100.0%

Figure S6 Safety analysis of 10 mg BID tofacitinib compared with 5 mg BID tofacitinib by five safety indicators.